Genomic testing helped identify which patients with node-negative, HR-positive, HER2- negative breast cancer could benefit from the addition of...
Combining real-world clinical and genomic data resulted in a more accurate prediction of outcomes compared to examining clinical and...
SAN ANTONIO – For patients with “good-risk” ductal carcinoma in situ (DCIS) who underwent breast-conserving surgery and did not...
SAN ANTONIO – Patients with intermediate-risk breast cancer had similar rates of 10-year overall survival whether or not they...
Recurrence risk was similar between active monitoring and usual care groups SAN ANTONIO – Among patients with hormone receptor...
SAN ANTONIO – Patients with low-risk ductal carcinoma in situ (DCIS) who underwent active monitoring reported comparable physical, emotional,...
Imlunestrant was effective in combination with abemaciclib, and as monotherapy in ESR1-mutated breast cancer SAN ANTONIO – Imlunestrant, an investigational...
SAN ANTONIO – Patients with germline BRCA mutations who were diagnosed with breast cancer at or before age 40...
SAN ANTONIO – Patients with high-risk, BRCA-positive breast cancer who received olaparib (Lynparza) after standard treatment continued to have...
SAN ANTONIO – The San Antonio Breast Cancer Symposium (SABCS) and the American Association for Cancer Research (AACR), an...